Breaking News

Gilead To Acquire YM BioSciences

December 12, 2012

Gains JAK Inhibitor set for Phase III trials

Gilead Sciences has signed a definitive agreement to acquire YM BioSciences in transaction valued at approximately $510 million in cash. The transaction is expected to close in 1Q13.
YM’s lead drug candidate, CYT387, is an oral selective inhibitor of the Janus kinase (JAK) family, which has been implicated in a number of disorders including myeloproliferative diseases, inflammatory disorders and certain cancers. YM reported positive results from a Phase I/II trial of CYT387 in patients with myelofibrosis. Following the acquisition, Gilead plans to initiate a Phase III trial of CYT387 in myelofibrosis in 1H13.
“This acquisition represents an opportunity to add a complementary clinical program in the area of hematologic cancers to our growing oncology portfolio,” said Norbert W. Bischofberger, Ph.D., Gilead’s executive vice president, R&D and chief scientific officer. “Based on promising Phase II data, we believe CYT387 could provide important clinical benefit for patients with myelofibrosis, including potential improvements with regard to anemia and decreased dependence on blood transfusions. We look forward to advancing CYT387 into a Phase 3 study as quickly as possible and to exploring its potential in other myeloproliferative diseases with significant unmet medical need.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks